- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Relmada Therapeutics Announces $160M Private Placement Financing
Oversubscribed financing led by major healthcare investors to fund R&D of oncology and CNS therapies.
Published on Mar. 9, 2026
Got story updates? Submit your updates here. ›
Relmada Therapeutics, a clinical-stage biotech company, announced it has entered into a $160 million private placement financing. The PIPE financing included participation from major healthcare investors like Venrock, RA Capital, and OrbiMed. Relmada plans to use the proceeds to advance the research and development of its lead drug candidates NDV-01 and sepranolone for oncology and central nervous system conditions.
Why it matters
This significant private financing will provide Relmada with the resources to accelerate the development of its promising therapeutic pipeline, which aims to address major unmet needs in oncology and CNS disorders. The oversubscribed nature of the deal demonstrates strong investor confidence in Relmada's science and management team.
The details
Under the terms of the agreement, Relmada is selling 29.5 million shares of common stock at $4.75 per share, as well as pre-funded warrants to purchase an additional 4.2 million shares at $0.001 per warrant. The financing is expected to close on or around March 11, 2026, subject to customary closing conditions.
- The PIPE financing is expected to close on or about March 11, 2026.
The players
Relmada Therapeutics, Inc.
A clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications.
Venrock Healthcare Capital Partners
A major healthcare-focused investment firm that participated in Relmada's private placement.
RA Capital Management
A prominent biotech-focused investment management firm that invested in Relmada's financing round.
OrbiMed
A leading global healthcare investment firm that joined Relmada's oversubscribed private placement.
What’s next
Relmada plans to use the net proceeds from the PIPE financing, together with existing cash, to advance the research and development of its product candidates.
The takeaway
This substantial private financing will provide Relmada with the necessary capital to accelerate the clinical development of its promising therapeutic pipeline, which aims to address significant unmet needs in oncology and central nervous system disorders.
